

HEAT BIOLOGICS, INC.
Form 8-K
June 24, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **June 22, 2015**

Heat Biologics, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35994
(Commission File Number)

26-2844103
(IRS Employer Identification No.)

801 Capitola Drive

Edgar Filing: HEAT BIOLOGICS, INC. - Form 8-K

Durham, NC 27713

(Address of principal executive offices and zip code)

(919) 240-7133

(Registrant's telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement

On June 22, 2015, Heat Biologics, Inc. (the Company) and certain of its subsidiaries entered into the First Amendment (the Amendment) to that certain Loan and Security Agreement with Square 1 Bank (the Bank), dated as of August 22, 2014 (the Agreement), which amended the following defined terms in Exhibit A to the Agreement, such that: (i) the Tranche III Funding Condition means Bank s receipt on or before June 30, 2015 of evidence satisfactory to the Bank of the initiation of the Company s Phase 1B trial for lung cancer indication; (ii) the Tranche IV Availability End Date is December 31, 2015; and (iii) the Tranche IV Funding Condition means Bank s receipt on or before December 31, 2015 of evidence satisfactory to the Bank of full enrollment of Company s Phase 1/2 clinical trial for HS-410. This brief summary does not purport to be complete and is subject to, and qualified in its entirety by reference to the First Amendment to Loan And Security Agreement which is attached as Exhibit 4.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is being filed as part of this Report.

| Exhibit Number | Description |
|---------------------------|---|
| <u>4.1</u> | First Amendment to Loan and Security Agreement with Square 1 Bank dated June 22, 2015 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 24, 2015 HEAT BIOLOGICS, INC.

| | |
|--------|-------------------------|
| By: | /s/ Jeffrey Wolf |
| Name: | Jeffrey Wolf |
| Title: | Chief Executive Officer |

EXHIBIT INDEX

| Exhibit Number | Description |
|---------------------------|---|
| <u>4.1</u> | First Amendment to Loan and Security Agreement with Square 1 Bank dated June 22, 2015 |